Peptide Policy Watch
Plain-English tracking of U.S. peptide and compounding regulation. We report what the FDA, the FTC and others have actually done, link the original document, and label anything we could not confirm. News and explanation only, never medical advice.
Latest
- Where peptide regulation stands right now: a plain-English timeline
A plain-English timeline of peptide regulation as of October 25, 2026: what FDA documents show, what is only reported, and what is still pending.
- This week in peptide policy: October 19–25, 2026
A quiet week for official peptide and compounding actions, October 19-25, 2026, with the reported HHS interim policy still under White House review.
- Telehealth and compounded drugs: what the FTC and FDA have actually said
What the FTC and FDA have each said about telehealth companies and compounded drugs, from public documents, and what each does not cover.
- FDA compounding categories explained: what Category 1 and Category 2 mean
What FDA's Category 1 and Category 2 labels for compounded bulk substances mean, and what they do not mean, using FDA's own documents.
How this site works
- Primary sources, dated. Every claim links to an official document or says it is reported by someone else. How we source.
- Reporting, not advice. We do not publish dosing, protocols or where to buy anything. The site owner is not a medical professional. Disclaimer.
- Independent. No sponsors and no affiliate links at this time. Affiliate disclosure.
- Who writes this. An independent individual publisher using AI-assisted drafting and a written checklist. Editorial team and editorial standards.
- Spot a mistake? Tell us and we will fix it and say so.